Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 19/20 | 1.00 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410444 | 1.00 | QPCT (1.00) | QPCTQPCTLMAOBGAA | |
| Hydrochloric Acid SCHEMBL245685 | 0.99 | QPCT (0.98) | QPCTQPCTLMAOBGAA | |
| SCHEMBL2081279 | 0.97 | QPCT (1.00) | QPCTQPCTLMAOB | |
| SCHEMBL78461 | 0.93 | QPCT (1.00) | QPCTQPCTLMAOB | |
| SCHEMBL76801 | 0.89 | QPCT (1.00) | QPCTQPCTLMAOBGAA | |
| SCHEMBL76307 | 0.87 | QPCT (1.00) | QPCTQPCTL | |
| SCHEMBL85708 | 0.86 | QPCT (0.79) | QPCTQPCTLMAOBGAA | |
| SCHEMBL77178 | 0.85 | QPCT (1.00) | QPCTQPCTLMAOBGAA | |
| SCHEMBL78943 | 0.85 | QPCT (1.00) | QPCTQPCTLMAOBGAA | |
| SCHEMBL77755 | 0.84 | QPCT (1.00) | QPCTQPCTLMAOBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220384684-A1 | DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-12-01 | — | — | US | claimed |
| US-20180318260-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2018-11-08 | — | — | US | claimed |
| WO-2017079547-A2 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-05-11 | — | — | WO | claimed |
| WO-2022250396-A1 | DISPLAY DEVICE AND METHOD FOR MANUFACTURING SAME | 삼성디스플레이 주식회사 | 2022-12-01 | — | — | WO | disclosed |
| US-20220384684-A1 | DISPLAY DEVICE AND METHOD OF MANUFACTURING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-12-01 | — | — | US | disclosed |
| EP-3747438-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747437-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019022600-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2019-01-31 | — | — | WO | disclosed |
| US-20180318260-A1 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | THE SCRIPPS RESEARCH INSTITUTE | 2018-11-08 | — | — | US | disclosed |
| EP-2082041-B1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| EP-2082041-B1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2008104580-A1 | NEW USE OF GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008034891-A2 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1713780-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191366-A1 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | GLS, QPCT, GLS2 | QPCT 2/4885QPCTL 11/4885MAOB 2442/4885 |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | QPCT 5/4885QPCTL 83/4885MAOB 1576/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | QPCT 5/4885QPCTL 83/4885MAOB 1576/4885 |
| US-20080249083-A1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | QPCT, QPCTL, GLUL | QPCT 1/4885QPCTL 2/4885MAOB 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.